crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lyf til að meðhöndla beinsjúkdóma - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - Ónæmisbælandi lyf - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
acetylcystein mylan freyðitafla 200 mg
mylan ab* - acetylcysteinum inn - freyðitafla - 200 mg
stamaril stungulyfsstofn og leysir, dreifa
sanofi pasteur* - gulusóttarveira 17d-204 stofn (lifandi, veikluð) - stungulyfsstofn og leysir, dreifa
amoxicillin sandoz mixtúruduft, dreifa 100 mg/ml
sandoz a/s* - amoxicillinum tríhýdrat - mixtúruduft, dreifa - 100 mg/ml
mucolysin freyðitafla 600 mg
sandoz a/s* - acetylcysteinum inn - freyðitafla - 600 mg
calcium sandoz freyðitafla 500 mg
sandoz a/s - calcii carbonas; calcii lacto-gluconas - freyðitafla - 500 mg
dolorin junior mixtúra, lausn 24 mg/ml
williams & halls ehf. - paracetamolum inn - mixtúra, lausn - 24 mg/ml
zofran mixtúra, lausn 0,8 mg/ml
sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml
bekemv
amgen technology (ireland) uc - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). sönnunargögn klínískum gagn er sýnt í sjúklinga með haemolysis með klínískum einkenni(s) marks um hár sjúkdómur starfsemi, óháð blóðgjöf sögu (sjá kafla 5.